are glp-1 covered by insurance Perspectives from employers on the costs and issues associated with covering agonists for weight loss Designing fiscally viable coverage of
Description
GLP-1 receptor agonists have garnered attention for their effectiveness in promoting weight loss

Its also essential to evaluate long-term weight loss goals and how either medication fits into an overall health and wellness plan

Patent expires in India, Canada, and Brazil by 2026, followed by U.S
However, the current scientific evidence does not strongly support their ability to boost GLP-1 levels in a way that meaningfully impacts your health

For example, the SELECT trial clearly demonstrated that semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease (Lincoff et al., 2023
